Sibutramine
As of the edition of 20 October 2026, Sibutramine is a small molecule: withdrawn from the market in 2010; acts on SLC6A2, SLC6A3 and SLC6A4; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2010
- Kind
- Small molecule
- Brand name
- Meridia
- First approved
- 22 November 1997 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Abbott
- Withdrawn from market
- 1 January 2010 (in some regions)
- Registered trials
- 24, 3 stopped early
- Disease areas
- Nutrition and metabolism; Mental health; Cancer; Heart and blood vessels; Hormones; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Sibutramine.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 4 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 2 | 0 | 1 |
| Phase 3 | 6 | 5 | 0 | 0 |
| Phase 4 | 10 | 7 | 0 | 2 |
| All trials | 24 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Abbott | Acquired holder and Lead sponsor of trials | 2000 to now |